All In Biotech

Drug Trial Radar · NCT06858865

A Study to Evaluate the Safety and Pharmacokinetics of AD-228A Compared to Coadministration of AD-2281 and AD-2282

An Open-label, Randomized, Single-dose, 2-sequence, 2-period, Crossover Study to Evaluate the Safety and Pharmacokinetics of AD-228A Compared to Coadministration of AD-2281 and AD-2282 in Healthy Adult Volunteers

Last checked: Nov 19, 2026Latest source record: Oct 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

60

Actual

Start

Jul 12, 2025

Primary completion

Aug 14, 2025

Study completion Aug 14, 2025

Sponsor

Lead sponsor
Addpharma Inc.Industry
Sponsor type
Industry
First posted
Mar 5, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Primary endpoint of this study is to evaluate the pharmacokinetic characteristics of AD-228A in healthy subjects.

Conditions

  • Primary Hypercholesterolaemia

Interventions

  • AD-228ADrug

    AD-228A Oral Tablet

  • AD-2281 and AD-2282Drug

    AD-2281 Oral Tablet + AD-2282 Oral Tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum concentration of drug in plasma (Cmax)Time frame: pre-dose to 72 hours
  2. Area under the plasma concentration-time curve during dosing interval (AUCt)Time frame: pre-dose to 72 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • H+ Yangji Hospital

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.